Lantern Pharma financials
$1.09−0.46%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$18.0M | -$22.2M | -$17.9M | -$14.4M | -$12.6M | -$5.9M |
| Net income | -$17.1M | -$20.8M | -$16.0M | -$14.3M | -$12.4M | -$5.9M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-1.57 | $-1.93 | $-1.47 | $-1.31 | $-1.13 | $-1.37 |
| EBITDA | -$18.0M | -$22.2M | -$17.9M | -$14.4M | -$12.4M | -$5.9M |
| Operating cash flow | -$15.7M | -$17.8M | -$14.3M | -$12.8M | -$10.6M | -$5.7M |
| Free cash flow | -$15.7M | -$17.8M | -$14.4M | -$12.8M | -$10.6M | -$5.7M |
| Diluted shares | 10.9M | 10.8M | 10.8M | 10.9M | 10.9M | 4.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.4M | $7.5M | $21.9M | $37.2M | $51.5M | $19.2M |
| Short-term investments | $5.7M | $16.5M | $19.4M | $18.0M | $19.2M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $108.5K |
| Total assets | $11.0M | $25.6M | $43.6M | $58.8M | $74.0M | $20.4M |
| Total liabilities | $4.5M | $4.4M | $2.7M | $2.8M | $2.4M | $660.8K |
| Shareholders' equity | $6.5M | $21.2M | $40.9M | $56.0M | $71.6M | $19.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology